No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
A theoretical framework for prescribing radiotherapy dose distributions using patient-specific biological information
1.“Prescribing, recording and reporting photon beam,” ICRU Report No. 50, Bethesda, MD, 1994.
2.“Prescribing, recording and reporting photon beam therapy (supplement to ICRU Report No. 50),” ICRU Report No. 62, Bethesda, MD, 2000.
3.S. Webb, P. M. Evans, W. Swindell and J. O. Deasy, “A proof that uniform dose gives the greatest TCP for fixed integral dose in the planning target volume,” Phys. Med. Biol. 39, 2091–2098 (1994).
4.K. Herholz, U. Pietrzyk, J. Voges, R. Schroder, M. Halber, H. Treuer, V. Sturm, and W. D. Heiss, “Correlation of glucose consumption and tumor cell density in astrocytomas: A stereotactic PET study,” Phys. Med. Biol. 79, 853–858 (1993).
5.S. M. Zhou, T. Z. Wong, and L. B. Marks, “Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation,” Med. Phys. 31, 2577–2583 (2004).
6.I. Koike, M. Ohmura, M. Hata, N. Takahashi, T. Oka, I. Ogino, J. Lee, T. Umezawa, K. Kinbara, K. Watai, Y. Ozawa, and T. Inoue, “FDG-PET scanning after radiation can predict tumor regrowth three months later,” Int. J. Radiat. Oncol., Biol., Phys. 57, 1231–1238 (2003).
7.A. Yaromina, T. Holscher, W. Eicheler, A. Rosner, M. Krause, F. Hessel, C. Petersen, H. D. Thames, M. Baumann, and D. Zips, “Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?” Radiother. Oncol. 76, 206–212 (2005).
8.Y. Belkacemi, P. Tsoutsou, N. Magne, P. Castadot, and D. Azria, “Metabolic functional imaging for tumor radiosensitivity monitoring,” Crit. Rev. Oncol. Hematol. 62, 227–239 (2007).
10.M. Ghilezan, D. Yan, J. Liang, D. Jaffray, J. Wong, and A. Martinez, “Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery,” Int. J. Radiat. Oncol., Biol., Phys. 60, 1602–1610 (2004).
11.X. H. Wang, R. Mohan, A. Jackson, S. A. Leibel, Z. Fuks, and C. C. Ling, “Optimization of intensity-modulated 3D conformal treatment plans based on biological indices,” Radiother. Oncol. 37, 140–152 (1995).
13.C. C. Ling, J. Humm, S. Larson, H. Amols, Z. Fuks, S. Leibel, and J. A. Koutcher, “Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality,” Int. J. Radiat. Oncol., Biol., Phys. 47, 551–560 (2000).
15.L. Xing, C. Cotrutz, S. Hunjan, A. L. Boyer, E. Adalsteinsson, and D. Spielman, “Inverse planning for functional image-guided intensity-modulated radiation therapy,” Phys. Med. Biol. 47, 3567–3578 (2002).
17.D. Levin-Plotnik and R. J. Hamilton, “Optimization of tumour control probability for heterogeneous tumours in fractionated radiotherapy treatment protocols,” Phys. Med. Biol. 49, 407–424 (2004).
18.Q. Wu, D. Djajaputra, H. H. Liu, L. Dong, R. Mohan and Y. Wu, “Dose sculpting with generalized equivalent uniform dose,” Med. Phys. 32, 1387–1396 (2005).
19.Y. Yang and L. Xing, “Towards biologically conformal radiation therapy (BCRT): Selective IMRT dose escalation under the guidance of spatial biology distribution,” Med. Phys. 32, 1473–1484 (2005).
20.A. Sovik, E. Malinen, O. S. Bruland, S. M. Bentzen and D. R. Olsen, “Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: A modelling study,” Phys. Med. Biol. 52, 499–513 (2007).
21.A. Sovik, E. Malinen, H. K. Skogma, S. M. Bentzen, O. S. Bruland, and D. R. Olsen, “Radiotherapy adapted to spatial and temporal variability in tumor hypoxia,” Int. J. Radiat. Oncol., Biol., Phys. 68, 1496–1504 (2007).
22.E. P. Malaise, B. Fertil, P. J. Deschavanne, N. Chavaudra, and W. A. Brock, “Initial slope of radiation survival curves is characteristic of the origin of primary and established cultures of human tumor cells and fibroblasts,” Radiat. Res. 111, 319–333 (1987).
23.D. J. Brenner and E. J. Hall, “Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy,” Int. J. Radiat. Oncol., Biol., Phys. 20, 181–190 (1991).
24.J. T. Leith, L. Quaranto, G. Padfield, S. Michelson, and A. Hercbergs, “Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: x-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo,” Int. J. Radiat. Oncol., Biol., Phys. 25, 283–287 (1993).
25.J. T. Leith, “In vitro radiation sensitivity of the LNCaP prostatic tumor cell line,” Prostate 24, 119–124 (1994).
26.S. M. Bentzen, “Steepness of the clinical dose-control curve and variation in the in vitro radiosensitivity of head and neck squamous cell carcinoma,” Int. J. Radiat. Biol. 61, 417–423 (1992).
28.A. E. Nahum, B. Movsas, E. M. Horwitz, C. C. Stobbe, and J. D. Chapman, “Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the alpha/beta ratio,” Int. J. Radiat. Oncol., Biol., Phys. 57, 391–401 (2003).
29.R. Kumar, H. Dhanpathi, S. Basu, D. Rubello, S. Fanti, and A. Alavi, “Oncologic PET tracers beyond and the novel quantitative approaches in PET imaging,” Q. J. Nucl. Med. Mol. Imaging 52, 50–65 (2008).
30.S. L. Tucker and H. D. Thames Jr., “The effect of patient-to-patient variability on the accuracy of predictive assays of tumor response to radiotherapy: A theoretical evaluation,” Int. J. Radiat. Oncol., Biol., Phys. 17, 145–157 (1989).
31.T. Bjork-Eriksson, C. West, E. Karlsson, and C. Mercke, “Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers,” Int. J. Radiat. Oncol., Biol., Phys. 46, 13–19 (2000).
32.S. Webb and A. E. Nahum, “A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density,” Phys. Med. Biol. 38, 653–666 (1993).
33.L. H. Gray, A. D. Conger, M. Ebert, S. Hornsey, and O. C. Scott, “The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy,” Br. J. Radiol. 26, 638–648 (1953).
34.E. A. Wright and P. Howard-Flanders, “The influence of oxygen on the radiosensitivity of mammalian tissues,” Acta Radiol. 48, 26–32 (1957).
35.B. Movsas, J. D. Chapman, A. L. Hanlon, E. M. Horwitz, R. E. Greenberg, C. Stobbe, G. E. Hanks, and A. Pollack, “Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: Preliminary findings,” Urology 60, 634–639 (2002).
36.A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske, and M. Hetzel, “Imaging proliferation in lung tumors with PET: -FLT versus -FDG,” J. Nucl. Med. 44, 1426–1431 (2003).
37.A. Laprie, I. Catalaa, E. Cassol, T. R. McKnight, D. Berchery, D. Marre, J. M. Bachaud, B. Berry, and E. C. J. Moyal, “Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: Predictive value for the site of postradiotherapy relapse in a prospective longitudinal study,” Int. J. Radiat. Oncol., Biol., Phys. 70, 773–781 (2008).
38.K. Lehtio, V. Oikonen, T. Gronroos, O. Eskola, K. Kalliokoski, J. Bergman, O. Solin, R. Grenman, P. Nuutila, and H. Minn, “Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with and fluoroerythronitroimidazole PET,” J. Nucl. Med. 42, 1643–1652 (2001).
39.D. Sorger, M. Patt, P. Kumar, L. I. Wiebe, H. Barthel, A. Seese, C. Dannenberg, A. Tannapfel, R. Kluge, and O. Sabri, “ fluoroazomycinarabinofuranoside and fluoromisonidazole : A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors,” Nucl. Med. Biol. 30, 317–326 (2003).
40.H. Barthel, H. Wilson, D. R. Collingridge, G. Brown, S. Osman, S. K. Luthra, F. Brady, P. Workman, P. M. Price, and E. O. Aboagye, “In vivo evaluation of fluoroetanidazole as a new marker for tumour hypoxia with positron emission tomography,” Br. J. Cancer 90, 2232–2242 (2004).
41.A. M. Spence, M. Muzi, K. R. Swanson, F. O’Sullivan, J. K. Rockhill, J. G. Rajendran, T. C. H. Adamsen, J. M. Link, P. E. Swanson, K. J. Yagle, R. C. Rostomily, D. L. Silbergeld, and K. A. Krohn, “Regional hypoxia in glioblastoma multiforme quantified with fluoromisonidazole positron emission tomography before radiotherapy: Correlation with time to progression and survival,” Clin. Cancer Res. 14, 2623–2630 (2008).
42.B. G. Wouters and J. M. Brown, “Cells at intermediate oxygen levels can be more important than the ‘hypoxic fraction’ in determining tumor response to fractionated radiotherapy,” Radiat. Res. 147, 541–550 (1997).
44.K. S. C. Chao, A. I. Blanco, and J. F. Dempsey, “A conceptual model integrating spatial information to assess target volume coverage for IMRT treatment planning,” Int. J. Radiat. Oncol., Biol., Phys. 56, 1438–1449 (2003).
45.M. Nordsmark, M. Hoyer, J. Keller, O. S. Nielsen, O. M. Jensen, and J. Overgaard, “The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas,” Int. J. Radiat. Oncol., Biol., Phys. 35, 701–708 (1996).
46.K. I. E. M. Wijffels, H. A. M. Marres, J. P. W. Peters, P. F. J. W. Rijken, A. J. van der Kogel, and J. H. A. M. Kaanders, “Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas,” Oral Oncol. 44, 335–344 (2008).
47.D. R. Wigg, Applied Radiobiology and Bioeffect Planning (Medical Physics, Madison, WI, 2001).
54.A. Nahum and J. D. Chapman, “In response to Dr. Wang et al..,” Int. J. Radiat. Oncol., Biol., Phys. 61, 310–311 (2005).
55.K. Lim, P. Chan, R. Dinniwell, A. Fyles, M. Haider, Y.-B. Cho, D. Jaffray, L. Manchul, W. Levin, R. P. Hill, and M. Milosevic, “Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: Radiobiologic modeling and correlation with tumor hypoxia,” Int. J. Radiat. Oncol., Biol., Phys. 70, 126–133 (2008).
56.Y.-J. Yang, J.-S. Ryu, S.-Y. Kim, S. J. Oh, K. C. Im, H. Lee, S.-W. Lee, K. J. Cho, G.-J. Cheon, and D. H. Moon, “Use of 3’-deoxy-3’- fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors,” Eur. J. Nucl. Med. Mol. Imaging 33, 412–419 (2006).
Article metrics loading...
Full text loading...
Most read this month